Boehringer eyes immuno-oncology; Roche plans more 'small' deals in 2015;

@FierceBiotech: Intrexon and Ziopharm buy into CAR-T in $100M deal. Story | Follow @FierceBiotech

@JohnCFierce: First #FDA approved obesity device since 2007. More | Follow @JohnCFierce

> Boehringer Ingelheim is buying into the promise of immunotherapies for cancer, signing a deal with Yale University to develop treatments that use the body's natural defenses to fight tumors. More

> Roche ($RHHBY) plans to consider its spree of bolt-on acquisitions in the new year, CFO Alan Hippe told Bloomberg, eschewing blockbuster mergers in favor of targeted M&A. "This continuous flow of rather small acquisitions makes total sense," Hippe said. Story

> Gene therapy specialist uniQure ($QURE) signed a deal with startup Treeway to develop a treatment for amyotrophic lateral sclerosis (ALS). News

Medical Device News

@FierceMedDev: This week's edition of FierceDiagnostics, hot off the press. | Follow @FierceMedDev

@StacyALawrence: ICYMI: JP Morgan: With $1.5B spent and a new president, NantHealth works to rationalize patient care. Report | Follow @StacyALawrence

@EmilyWFierce: Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. FiercePharmaMarketing story | Follow @EmilyWFierce

> Bard loses bid to delay vaginal mesh trial proceedings. Article

> DexCom: new CEO reports patient base grew by 50% in 2014. More

> Stakeholders look for clues to FDA's 2015 intentions regarding health IT. Story

Pharma News

@FiercePharma:  JPM: $GSK ready to shift off Advair; $TEVA CEO lists buyout reqs; $PFE building PCSK9 "franchise." Article | Follow @FiercePharma

@CarlyHFierce:  Big Pharma vs. 'growth pharma'? Let Actavis chief detail the differences. More | Follow @CarlyHFierce

> With hep C price deals made, Express Scripts eyes PCSK9 meds--and then cancer. Article

> German cost gatekeeper spurns Gilead's Zydelig for CLL. Story

> Drug adherence gets a boost from gamification, new study says. More

Drug Delivery News

> Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents. More

> Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story

> Pill-maker Capsugel collects Australian uni's tech for greater bioavailability. Article

> Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality. Item

> Alnylam and Isis strengthen RNAi alliance, agree to swap IP. More

Diagnostics News

> Roche snatches up majority share in Foundation Medicine for $1B plus milestones. News

> Biocept joins up with Insight Genetics for lung cancer test. Report

> Qiagen acquires Enzymatics, gains NGS partner ArcherDX. Story

> Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx. More

> Qiagen exceeds 2014 placement goals for molecular Dx, hedges its bets on continued success. Article

Pharma Marketing News

> Shire CEO sees 'home turf' marketing advantage with NPS buy. Report

> Actavis CEO: We may be big, but we don't want to be Big Pharma. News

> Some ad types are calling it: 'Pharmageddon' is over. DTC is back. Article

> Turning drug adherence into a game actually works, study finds. Report

> Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. More

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.